Cortivazol

Summary

Cortivazol (CHEMBL2105842) is an approved small molecule (ATC H02AB17); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: H02AB17
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 530.7 Da · C32H38N2O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105842
Name	Cortivazol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	66249
ATC	H02AB17
Molecular formula	C32H38N2O5
Molecular weight	530.7
InChIKey	RKHQGWMMUURILY-UHRZLXHJSA-N

SMILES: C[C@@H]1C[C@H]2[C@@H]3C=C(C4=CC5=C(C[C@@]4([C@H]3[C@H](C[C@@]2([C@]1(C(=O)COC(=O)C)O)C)O)C)C=NN5C6=CC=CC=C6)C

IUPAC name: [2-[(1S,2R,13S,14S,16R,17R,18S,20S)-17,20-dihydroxy-2,11,16,18-tetramethyl-7-phenyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5,9,11-tetraen-17-yl]-2-oxoethyl] acetate

Also known as: Altim, Cortivazol, NSC-80998, CORTIVAZOL

Patent coverage: 2,537 distinct patent families (8,151 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE2/PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00804895	PHASE2/PHASE3	COMPLETED	Cluster Headache Cortivazol Injection (CHCI)
NCT02793440	Not specified	UNKNOWN	Effectiveness of Lumbar Traction in Lumbar Disk Herniation

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).